Johan Qalaba, I Nyoman Bayu Mahendra Mahendra, I Gde Sastra Winata, A.A.N Jaya Kusuma Kusuma, I Nyoman Gede Budiana, Kadek Fajar Marta

High survivin expression as a risk factor for poor response to neoadjuvant paclitaxel-carboplatin chemotherapy in cervical cancer stages IB3, IIA2, & IIB

Introduction

High survivin expression as a risk factor for poor response to neoadjuvant paclitaxel-carboplatin chemotherapy in cervical cancer stages ib3, iia2, & iib . High survivin expression is linked to poor response to paclitaxel-carboplatin neoadjuvant chemotherapy in cervical cancer (stages IB3, IIA2, IIB), a key predictive biomarker.

Abstract

Introduction: Cervical cancer remains a frequently encountered malignancy among women and continues to contribute substantially to cancer-related mortality. Survivin, a key regulator of apoptosis and the cell cycle, has been widely reported to exhibit elevated expression across multiple tumor types, including cervical carcinoma. Considering that inadequate responses to neoadjuvant chemotherapy remain a major therapeutic challenge, biomarkers capable of predicting treatment outcomes are urgently needed. This study aimed to examine whether heightened Survivin expression is associated with reduced responsiveness to neoadjuvant paclitaxel–carboplatin therapy in patients diagnosed with cervical cancer at FIGO stages IB3, IIA2, and IIB. Methods: A nested case–control study was conducted from June to September 2024 involving 56 cervical cancer patients, comprising 28 individuals with poor chemotherapy response and 28 with good response. Survivin expression in cervical tissue samples was evaluated using immunohistochemical methods. Results: Analysis revealed that elevated Survivin levels were significantly linked to unfavorable chemotherapy outcomes, with an odds ratio of 3.263 (95% CI: 1.09–9.78; p = 0.032). These findings indicate that higher Survivin expression increases the likelihood of inadequate therapeutic response to paclitaxel–carboplatin treatment in cervical carcinoma. Conclusion: High Survivin expression is associated with diminished response to neoadjuvant paclitaxel–carboplatin chemotherapy in cervical cancer stages IB3, IIA2, and IIB. Additional research is warranted to further establish the potential of Survivin as a predictive biomarker for treatment response in cervical cancer.

Full Text

Comments

You need to be logged in to post a comment.